Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data. (October 2021) - Remák, Edit; Hawkins, Neil; Jones, Trefor; Otley, Marissa; Twigger, Robert; Prince, Miles